SCHEMBL5209072

SCHEMBL5209072

CC(C)(C)OC(=O)[C@H](N)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
PTGS1 P23219 1/20 0.39
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
NOS1 P29475 2/20 0.36
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
SLC7A5 Q01650 3/20 0.35
LMNA P02545 1/20 0.33
DGAT1 O75907 1/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33
AAK1 Q2M2I8 1/20 0.31
LTA4H P09960 1/20 0.31
CA12 O43570 1/20 0.31
CA14 Q9ULX7 1/20 0.31
GRIK1 P39086 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221769 1.00 ALDH1A1 (0.39) ALDH1A1MAPTPTGS1KMT2AMEN1
SCHEMBL1353684 0.87 NOS1 (0.39) ALDH1A1MAPTPTGS1KMT2AMEN1
SCHEMBL5346485 0.81 MEN1 (0.35) KMT2AMEN1GAANOS1NOS3
SCHEMBL5409743 0.81 NOS1 (0.36) ALDH1A1MAPTPTGS1KMT2ANOS1
SCHEMBL16340968 0.81 NOS1 (0.39) ALDH1A1MAPTPTGS1KMT2ANOS1
SCHEMBL28113585 0.81 NOS1 (0.36) ALDH1A1MAPTPTGS1KMT2ANOS1
SCHEMBL3204138 0.79 SLC7A5 (0.42) ALDH1A1MAPTPTGS1KMT2AMEN1
SCHEMBL523836 0.79 DGAT1 (0.41) KMT2AMEN1GAANOS1NOS3
SCHEMBL27549577 0.79 NOS1 (0.35) KMT2ANOS1NOS3NOS2LMNA
SCHEMBL4106257 0.77 KMT2A (0.39) ALDH1A1MAPTPTGS1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265140-B2 Acyloxymethylcarbamate prodrugs of oxazolidinones PFIZER INC (US) 2007-09-04 US claimed
EP-1668005-B1 ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES PHARMACIA & UPJOHN CO LLC (US) 2007-02-14 EP claimed
EP-1668005-A1 ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES Pharmacia & Upjohn Company LLC (US) 2006-06-14 EP claimed
US-20050267104-A1 E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria PHARMACIA & UPJOHN COMPANY LLC 2005-12-01 US claimed
WO-2005028473-A1 ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY LLC (US) 2005-03-31 WO claimed
US-7265140-B2 Acyloxymethylcarbamate prodrugs of oxazolidinones PFIZER INC (US) 2007-09-04 US disclosed
EP-1668005-B1 ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES PHARMACIA & UPJOHN CO LLC (US) 2007-02-14 EP disclosed
EP-1668005-A1 ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES Pharmacia & Upjohn Company LLC (US) 2006-06-14 EP disclosed
US-20050267104-A1 E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria PHARMACIA & UPJOHN COMPANY LLC 2005-12-01 US disclosed
WO-2005028473-A1 ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY LLC (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267104-A1 E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria HDAC3, HDAC1, OGA ALDH1A1 591/4885MAPT 4167/4885PTGS1 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.